Stock Research for ONTX

ONTX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ONTX Stock Chart & Research Data

The ONTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ONTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ONTX Due diligence Resources & Stock Charts

The ONTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ONTX Detailed Price Forecast - CNN Money CNN View ONTX Detailed Summary - Google Finance
Yahoo View ONTX Detailed Summary - Yahoo! Finance Zacks View ONTX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ONTX Trends & Analysis - Trade-Ideas Barrons View ONTX Major Holders - Barrons
NASDAQ View ONTX Call Transcripts - NASDAQ Seeking View ONTX Breaking News & Analysis - Seeking Alpha
Spotlight View ONTX Annual Report - CompanySpotlight.com OTC Report View ONTX OTC Short Report - OTCShortReport.com
TradeKing View ONTX Fundamentals - TradeKing Charts View ONTX SEC Filings - Bar Chart
WSJ View Historical Prices for ONTX - The WSJ Morningstar View Performance/Total Return for ONTX - Morningstar
MarketWatch View the Analyst Estimates for ONTX - MarketWatch CNBC View the Earnings History for ONTX - CNBC
StockMarketWatch View the ONTX Earnings - StockMarketWatch MacroAxis View ONTX Buy or Sell Recommendations - MacroAxis
Bullish View the ONTX Bullish Patterns - American Bulls Short Pains View ONTX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ONTX Stock Mentions - StockTwits PennyStocks View ONTX Stock Mentions - PennyStockTweets
Twitter View ONTX Stock Mentions - Twitter Invest Hub View ONTX Investment Forum News - Investor Hub
Yahoo View ONTX Stock Mentions - Yahoo! Message Board Seeking Alpha View ONTX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ONTX - SECform4.com Insider Cow View Insider Transactions for ONTX - Insider Cow
CNBC View ONTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ONTX - OTC Markets
Yahoo View Insider Transactions for ONTX - Yahoo! Finance NASDAQ View Institutional Holdings for ONTX - NASDAQ


Stock Charts

FinViz View ONTX Stock Insight & Charts - FinViz.com StockCharts View ONTX Investment Charts - StockCharts.com
BarChart View ONTX Stock Overview & Charts - BarChart Trading View View ONTX User Generated Charts - Trading View




Latest Financial News for ONTX


Onconova Welcomes Avi Oler, JD, MBA, as Vice President, Corporate Development and General Counsel
Posted on Monday December 10, 2018

Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that Mr. Abraham “Avi” Oler has joined Onconova’s management team as Vice President, Corporate Development and General Counsel.  Mr. Oler will be primarily responsible for business development, investor relations, and legal affairs of the Company. To help further advance Rigosertib, the Company’s Phase 3 candidate for MDS, Mr. Oler’s focus will be on forging new collaborations in additional geographies.  Rigosertib is currently partnered with SymBio Pharmaceuticals for Japan and Korea, and with Pint Pharma for Latin America.  Information about partnering opportunities can be obtained via e-mail at bd@onconova.us or via the Company’s website: https://www.onconova.com/partnering.


Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
Posted on Monday December 03, 2018

Overall response rate (ORR) of 90% reported in this multi-institutional Phase 2 study in hypomethylating agent (HMA) naïve patients, including Complete Remission (CR) rate of.


Edited Transcript of ONTX earnings conference call or presentation 13-Nov-18 2:00pm GMT
Posted on Friday November 16, 2018

Q3 2018 Onconova Therapeutics Inc Earnings Call


Onconova Therapeutics Announces Business Highlights and Financial Results for Third Quarter 2018
Posted on Tuesday November 13, 2018

Conference Call Today at 9:00 a.m. Eastern Time NEWTOWN, Pa., Nov. 13, 2018 -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company focused on.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.